112972-64-2

Upstream product

• 7051-16-3 1-chloro-3,5-dimethoxybenzene 
• 139027-35-3 5-Chloro-7-methoxy-3-(4-methoxy-phenyl)-chromen-4-one 
• 4693-91-8 4-methoxyphenyl-acetic chloride 

Downstream Products

• 112953-90-9 ethyl {[5-chloro-3-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetate 
• 112953-61-4 [5-Chloro-3-(4-methoxy-phenyl)-4-oxo-4H-chromen-7-yloxy]-acetic acid 
• 112953-60-3 [5-Chloro-3-(4-hydroxy-phenyl)-4-oxo-4H-chromen-7-yloxy]-acetic acid 
• 112953-80-7 ethyl {[5-chloro-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetate 

Relevant academic research and scientific papers

Estrogen Receptor-beta ligands

A method for treating a disease associated with the estrogen receptor-β, comprising the step of administiering a therapeutically-effective amount of a compound that satifies the equation: KiαA/KiβA>25, optionally having general structure (I).

Aryloxyacetic acid diuretics with uricosuric activity. II. Substituted [(4-oxo-4H-1-benzopyran-7-yl)oxy]acetic acids and the related compounds

Di- and tri-substituted [(4-oxo-4H-1-benzopyran-7-yl)oxy]acetic acids, and 4-oxo-3-phenyl-4H-furo[2,3-h][1]benzopyran-8-carboxylic acid were synthesized and tested for natriuretic and uricosuric activities. Among the compounds tested, 3,5-disubstituted [(4-oxo-4H-1-benzopyran-7-yl)oxy]acetic acids (6c-f, h, n and x) showed potent natriuretic and uricosuric activities, whereas 4-oxo-3-phenyl-4H-furo[2,3-h][1]benzopyran-8-carboxylic acid (6dd) possessed only potent natriuretic activity. The structure-activity relationships are also discussed.